Compare Inovio Pharmaceuticals Inc (INO) vs Marathon Digital Holdings Inc (MARA) Price & Performance

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

MARA Holdings trades at $9.675, down 1.2% on the day, with a bearish technical signal and negative earnings trends. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, while revenue declined to $804 million in 2026. Despite a 50% analyst buy rating and a $16.08 consensus price target, profitability remains challenged with a -429.71% net income margin. Recent news highlights a strategic pivot toward AI digital infrastructure amid Bitcoin mining headwinds.

The outlook is mixed: valuation ratios like P/E of 3.37 suggest potential undervaluation, but persistent losses and high debt-to-asset ratio of 49.43% pose significant risks. Upside depends on successful execution of the AI infrastructure strategy, while downside risks include continued earnings misses and cryptocurrency market volatility.